EP0351908A1 - Lebende Newcastle-Krankheit-Virus-Vakzine - Google Patents

Lebende Newcastle-Krankheit-Virus-Vakzine Download PDF

Info

Publication number
EP0351908A1
EP0351908A1 EP89201837A EP89201837A EP0351908A1 EP 0351908 A1 EP0351908 A1 EP 0351908A1 EP 89201837 A EP89201837 A EP 89201837A EP 89201837 A EP89201837 A EP 89201837A EP 0351908 A1 EP0351908 A1 EP 0351908A1
Authority
EP
European Patent Office
Prior art keywords
strain
virus
vaccination
ndw
vaccinated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP89201837A
Other languages
English (en)
French (fr)
Other versions
EP0351908B1 (de
Inventor
Nico C/O Octrooibureau Zoan B.V. Van Wiltenburg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dimminaco AG
Original Assignee
Duphar International Research BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duphar International Research BV filed Critical Duphar International Research BV
Publication of EP0351908A1 publication Critical patent/EP0351908A1/de
Application granted granted Critical
Publication of EP0351908B1 publication Critical patent/EP0351908B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/816—Viral vaccine for avian species, e.g. poultry or other birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines

Definitions

  • the invention relates to live Newcastle Disease virus (NDV)vaccines for poultry, to a method of preparing the same and to a new NDV-strain.
  • NDV Newcastle Disease virus
  • ND is a disorder of the respiratory tract, the laying system, the intestines and the central nervous system, frequently occurring in poultry.
  • the disease causes great economical losses in poultry farming. In addition to mortality of animals, the disease causes respiratory and nervous symptoms, and in layers decrease of production as result of damage to the laying system.
  • the disease is controlled by vaccinating the animals with a live or an inactivated vaccine.
  • vaccinations with live vaccines based on among others the Hitchner-­strain or the De la Sota-strain have been caried out for a considerable period of time already.
  • the use of vaccines based on the said known NDV strains is comparati­vely safe and effective, it has been found that in the vaccination of young chickens a strong vaccination reaction nevertheless occurs when the vaccination is done with a strain which provides a good protection. On the other hand the protection is not complete when vaccination is carried out with a strain which causes little vaccination reaction.
  • the maternal immunity plays an important role since, for causing the vaccination in chickens with a maternal immunity to be effective, vaccination strains are required which cause a considerable vaccination reaction.
  • NDV-vaccines based on the known strains is that vaccination with combination vaccines against ND and infectious bronchitis (IB) is not possible due to the occurrence of unacceptably strong vaccination reactions.
  • vaccine according to the invention may be used already at an age of 1 day.
  • the NDW virus strain can be processed in a manner known per se to a vaccine suitable for administration.
  • a vaccine may be adminstered to chickens from the age of 1 day or at a later date, even when they have a high maternal immunity, if desired in combination with one or more IB-virus strains.
  • the administration may be carried out, for example, by means of a spray or eyedrops.
  • 43 chickens were vaccinated with 10log 5.4 EID50 per bird by means of spray vaccination. 3 and 6 weeks after vaccination 21 and 22 birds, respectively, were subjected to a challenge infection with 10log 6 ELD50 of Herts 33 virus, administered ocularly, per bird. As a control, at the time of challenge, 2 SPF chickens, 1 week older than the broilers, were added and also challenged.
  • broilers having a mean maternal antibody titer of 2log 10.7 HI units were vaccinated by means of spray at the age of 1 day with a combination vaccine consisting of 10log 5.4 EID50 NDW and 10log 4.0 EID50 H120/84-3 per dose.
  • 25 birds were taken from a group of 75 day-old broilers for the determination of the maternal antibody titer according to the HI-method.
  • the mean titer was found to be 2log 8.7.
  • the remaining chickens were divided into two groups of 25.
  • the first group was vaccinated with a combination vaccine NDW/H120/84-3 in a manner identical to that of experiment 2.
  • the second group formed the non-­vaccinated control group.
  • One bird from this group died in the period before challenge.
  • Both groups were infected 32 days post vaccination with 10log 6.5 ELD50 of Herts 33 virus per bird.
  • Two SPF chickens of approximately 6 weeks old were added and also challenged.
  • the trachea lesion score determined at 10 days post vaccination, was - 0.0 for the non-vaccinated birds - 0.1- 0.6- 0.7- 1.1 for the birds vaccinated with IB Primer (4 groups of 10 birds each) - 0.0- 0.0- 0.2- 0.8 for the birds vaccinated with IB Primer/NDW combination (4 groups of 10 birds each)
  • the mean ND HI titer determined at 0, 3 and 6 weeks post vaccination was - 8.2 (maternal immunity) 4.0 and 4.0, respectively, for birds vaccinated with IB Primer, - 8.2, 5.2 and 6.4, respectively, for the birds vaccinated with IB Primer/NDW combination.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP89201837A 1988-07-18 1989-07-12 Lebende Newcastle-Krankheit-Virus-Vakzine Expired - Lifetime EP0351908B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL8801819 1988-07-18
NL8801819 1988-07-18

Publications (2)

Publication Number Publication Date
EP0351908A1 true EP0351908A1 (de) 1990-01-24
EP0351908B1 EP0351908B1 (de) 1994-10-05

Family

ID=19852645

Family Applications (1)

Application Number Title Priority Date Filing Date
EP89201837A Expired - Lifetime EP0351908B1 (de) 1988-07-18 1989-07-12 Lebende Newcastle-Krankheit-Virus-Vakzine

Country Status (9)

Country Link
US (1) US5149530A (de)
EP (1) EP0351908B1 (de)
JP (1) JP2655726B2 (de)
AT (1) ATE112490T1 (de)
DE (1) DE68918649T2 (de)
DK (1) DK175318B1 (de)
ES (1) ES2060740T3 (de)
HU (1) HU204439B (de)
IE (1) IE65736B1 (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0541418A1 (de) * 1991-10-29 1993-05-12 Rhone Merieux S.A. Zubereitung der Antigene und Impfstoffe vom Mystery-Disease-Virus, erworbene Antigene und Impfstoffe zur Verhütung dieser Krankheit
EP0760394A1 (de) * 1995-08-01 1997-03-05 Akzo Nobel N.V. Milder Newcastle-Krankheitsimpfstoff
EP0770397A1 (de) * 1995-10-18 1997-05-02 Akzo Nobel N.V. Newcastle-Krankheitsvirus-Kombinationsimpfstoff
EP0848956A1 (de) * 1996-12-17 1998-06-24 Dimminaco Ag/Sa/Ltd. In ovo Impfung gegen die Newcastle-Krankheit

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250298A (en) * 1988-10-07 1993-10-05 University Of Delaware Live attenuated newcastle disease virus vaccines and preparation thereof
TW200502402A (en) * 2002-12-06 2005-01-16 Wyeth Corp Escape mutants of newcastle disease virus as marker vaccines

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798835A (en) * 1954-01-18 1957-07-09 American Cyanamid Co Newcastle disease and infectious bronchitis vaccines and production thereof
BE853923A (fr) * 1977-04-25 1977-10-25 Rit Rech Ind Therapeut Nouveau vaccin vivant ameliore contre le pseudopeste aviaire et son procede de preparation
GB2062461A (en) * 1979-10-29 1981-05-28 Vg N Kontrol Veterinar Prep Vaccine against newcastle fowl disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3876763A (en) * 1970-12-29 1975-04-08 Shionogi & Co Infectious coryza infectious bronchitis and newcastle disease vaccines and production thereof
US4053583A (en) * 1976-03-01 1977-10-11 Smithkline Corporation Live newcastle disease virus vaccines
DE2966914D1 (en) * 1978-09-14 1984-05-24 Gist Brocades Nv Combined vaccine active against newcastle disease and egg production drop caused by adeno-like viruses, process for preparing it, adeno-like and newcastle disease virus strains

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798835A (en) * 1954-01-18 1957-07-09 American Cyanamid Co Newcastle disease and infectious bronchitis vaccines and production thereof
BE853923A (fr) * 1977-04-25 1977-10-25 Rit Rech Ind Therapeut Nouveau vaccin vivant ameliore contre le pseudopeste aviaire et son procede de preparation
GB2062461A (en) * 1979-10-29 1981-05-28 Vg N Kontrol Veterinar Prep Vaccine against newcastle fowl disease

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0541418A1 (de) * 1991-10-29 1993-05-12 Rhone Merieux S.A. Zubereitung der Antigene und Impfstoffe vom Mystery-Disease-Virus, erworbene Antigene und Impfstoffe zur Verhütung dieser Krankheit
EP0760394A1 (de) * 1995-08-01 1997-03-05 Akzo Nobel N.V. Milder Newcastle-Krankheitsimpfstoff
US5750111A (en) * 1995-08-01 1998-05-12 Akzo Nobel N.V. Mild newcastle disease virus vaccine
EP0770397A1 (de) * 1995-10-18 1997-05-02 Akzo Nobel N.V. Newcastle-Krankheitsvirus-Kombinationsimpfstoff
US5733556A (en) * 1995-10-18 1998-03-31 Akzo Nobel N.V. Newcastle disease virus combination vaccine
EP0848956A1 (de) * 1996-12-17 1998-06-24 Dimminaco Ag/Sa/Ltd. In ovo Impfung gegen die Newcastle-Krankheit
WO1998026800A1 (en) * 1996-12-17 1998-06-25 Dimminaco Ag In ovo vaccination against newcastle disease
KR100540856B1 (ko) * 1996-12-17 2006-01-12 딤미나코 아게 뉴우캐슬병에 대한 난내 백신접종

Also Published As

Publication number Publication date
JP2655726B2 (ja) 1997-09-24
ATE112490T1 (de) 1994-10-15
DE68918649D1 (de) 1994-11-10
DK347189A (da) 1990-01-19
IE892284L (en) 1990-01-18
DK347189D0 (da) 1989-07-13
US5149530A (en) 1992-09-22
HU204439B (en) 1992-01-28
DK175318B1 (da) 2004-08-16
HUT52703A (en) 1990-08-28
EP0351908B1 (de) 1994-10-05
JPH0269422A (ja) 1990-03-08
ES2060740T3 (es) 1994-12-01
DE68918649T2 (de) 1995-03-23
IE65736B1 (en) 1995-11-15

Similar Documents

Publication Publication Date Title
US4530831A (en) Infectious Bursal Disease vaccine
JPH09169663A (ja) 組合わせタイプのニューカッスル病ウイルスワクチン
US7462479B2 (en) Infectious bronchitis virus vaccine
EP0351908B1 (de) Lebende Newcastle-Krankheit-Virus-Vakzine
US6159472A (en) Intradermal Avian immunization with inactivated vaccines
JP3945842B2 (ja) 弱毒性ニューカッスル病ウイルスワクチン
EP0600723B1 (de) Impfstoff gegen infektiöse Bursal-Krankheit
MXPA96003124A (en) Vaccine against the newcastle beni disease virus
KR920005661B1 (ko) 생 조합 백신
HUT62200A (en) Cell-free virus vaccine for marek disease
EP0967991B1 (de) Vakzine gegen infektiöse bursitis
EP0212703B1 (de) Impfstoffe für einen Tag alte Hühner gegen die infektiöse Bronchitis
EP0069407B1 (de) Verfahren zur Immunisierung von Schweinen gegen die Aujeszky-Krankheit
US5436005A (en) Low virulence infectiouns laryngotracheitis (ILT) virus for vaccinating birds
Guittet et al. Efficiency of Oil Adjuvanted Infectious Bronchitis Vaccines
Solvay Duphar et al. AN ULsTER 2c sTRAIN DERVED vACCINE
RU2166328C2 (ru) Сухая вакцина против реовирусного теносиновита кур
Kelleher et al. EVALUATION OF THE NEHCASTLE DISEASE VACCINATION PROGRAMS OF TURKEYS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19900713

17Q First examination report despatched

Effective date: 19920323

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 112490

Country of ref document: AT

Date of ref document: 19941015

Kind code of ref document: T

REF Corresponds to:

Ref document number: 68918649

Country of ref document: DE

Date of ref document: 19941110

ET Fr: translation filed
ITF It: translation for a ep patent filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2060740

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3013729

EAL Se: european patent in force in sweden

Ref document number: 89201837.5

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. PATENTANWAELTE

Ref country code: CH

Ref legal event code: PUE

Owner name: DUPHAR INTERNATIONAL RESEARCH B.V. TRANSFER- DIMMI

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

NLS Nl: assignments of ep-patents

Owner name: DIMMINACO AG

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: DIMMINACO AG

Free format text: DIMMINACO AG#ZUERICHSTRASSE 12#8134 ADLISWIL (CH) -TRANSFER TO- DIMMINACO AG#ZUERICHSTRASSE 12#8134 ADLISWIL (CH)

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20080708

Year of fee payment: 20

Ref country code: CH

Payment date: 20080708

Year of fee payment: 20

Ref country code: DE

Payment date: 20080731

Year of fee payment: 20

Ref country code: LU

Payment date: 20080731

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20080619

Year of fee payment: 20

Ref country code: AT

Payment date: 20080616

Year of fee payment: 20

Ref country code: FR

Payment date: 20080707

Year of fee payment: 20

Ref country code: IT

Payment date: 20080718

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20080616

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20080730

Year of fee payment: 20

Ref country code: SE

Payment date: 20080708

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20080704

Year of fee payment: 20

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20090711

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 20090712

EUG Se: european patent has lapsed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20090713

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20090713

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20090712

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20090711